In addition to describing the relationship between germline variation and the CD8+ TCR repertoire in patients with cancer, our findings support an interaction between genetic effects on the repertoire and ICB treatment with evidence that this relationship has prognostic implications. This evidence concerns the gene CD8A and cancer.